Top

Published in:

Open Access 01-12-2009 | Review

RAGE (Receptor for Advanced Glycation Endproducts), RAGE Ligands, and their role in Cancer and Inflammation

Authors: Louis J Sparvero, Denise Asafu-Adjei, Rui Kang, Daolin Tang, Neilay Amin, Jaehyun Im, Ronnye Rutledge, Brenda Lin, Andrew A Amoscato, Herbert J Zeh, Michael T Lotze

Published in: Journal of Translational Medicine | Issue 1/2009

Abstract

The Receptor for Advanced Glycation Endproducts [RAGE] is an evolutionarily recent member of the immunoglobulin super-family, encoded in the Class III region of the major histocompatability complex. RAGE is highly expressed only in the lung at readily measurable levels but increases quickly at sites of inflammation, largely on inflammatory and epithelial cells. It is found either as a membrane-bound or soluble protein that is markedly upregulated by stress in epithelial cells, thereby regulating their metabolism and enhancing their central barrier functionality. Activation and upregulation of RAGE by its ligands leads to enhanced survival. Perpetual signaling through RAGE-induced survival pathways in the setting of limited nutrients or oxygenation results in enhanced autophagy, diminished apoptosis, and (with ATP depletion) necrosis. This results in chronic inflammation and in many instances is the setting in which epithelial malignancies arise. RAGE and its isoforms sit in a pivotal role, regulating metabolism, inflammation, and epithelial survival in the setting of stress. Understanding the molecular structure and function of it and its ligands in the setting of inflammation is critically important in understanding the role of this receptor in tumor biology.

Available only for authorised users

Yan SF, Ramasamy R, Schmidt AM: Mechanisms of Disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab. 2008, 4 (5): 285-293.PubMed

Clynes R, Moser B, Yan S, Ramasamy R, Herold K, Schmidt A: Receptor for AGE (RAGE): weaving tangled webs within the inflammatory response. Current Molecular Medicine. 2007, 7: 743-751.PubMed

Herold K, Moser B, Chen Y, Zeng S, Yan SF, Ramasamy R, Emond J, Clynes R, Schmidt AM: Receptor for advanced glycation end products (RAGE) in a dash to the rescue: inflammatory signals gone awry in the primal response to stress. J Leukoc Biol. 2007, 82: 204-212.PubMed

Bierhaus A, Humpert P, Morcos M, Wendt T, Chavakis T, Arnold B, Stern D, Nawroth P: Understanding RAGE, the receptor for advanced glycation end products. Journal of Molecular Medicine. 2005, 83: 876-886.PubMed

Srikrishna G, Huttunen HJ, Johansson L, Weigle B, Yamaguchi Y, Rauvala H, Freeze HH: N-Glycans on the receptor for advanced glycation end products influence amphoterin binding and neurite outgrowth. Journal of Neurochemistry. 2002, 80: 998-1008.PubMed

Hudson BI, Kalea AZ, Arriero MdM, Harja E, Boulanger E, D'Agati V, Schmidt AM: Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42. J Biol Chem. 2008, 283: 34457-34468.PubMedCentralPubMed

Foell D, Wittkowski H, Roth J: Mechanisms of Disease: a 'DAMP' view of inflammatory arthritis. Nature Clinical Practice Rheumatology. 2007, 3: 382-390.PubMed

Schmidt AM, Vianna M, Gerlach M, Brett J, Ryan J, Kao J, Esposito C, Hegarty H, Hurley W, Clauss M: Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem. 1992, 267: 14987-14997.PubMed

Schmidt A, Yan S, Yan S, Stern D: The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. Journal of Clinical Investigation. 2001, 108: 949-955.PubMedCentralPubMed

10.

Liliensiek B, Weigand M, Bierhaus A, Nicklas W, Kasper M, Hofer S, Plachky J, Grone H, Kurschus F, Schmidt A: Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest. 2004, 113: 1641-1650.PubMedCentralPubMed

11.

Xie J, Reverdatto S, Frolov A, Hoffmann R, Burz DS, Shekhtman A: Structural basis for pattern recognition by the receptor for advanced glycation end products (RAGE). J Biol Chem. 2008, 283: 27255-27269.PubMed

12.

Raucci A, Cugusi S, Antonelli A, Barabino SM, Monti L, Bierhaus A, Reiss K, Saftig P, Bianchi ME: A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J. 2008, 22: 3716-3727.PubMed

13.

Zhang L, Bukulin M, Kojro E, Roth A, Metz VV, Fahrenholz F, Nawroth PP, Bierhaus A, Postina R: Receptor for Advanced Glycation End Products Is Subjected to Protein Ectodomain Shedding by Metalloproteinases. J Biol Chem. 2008, 283: 35507-35516.PubMed

14.

Galichet A, Weibel M, Heizmann CW: Calcium-regulated intramembrane proteolysis of the RAGE receptor. Biochemical and Biophysical Research Communications. 2008, 370: 1-5.PubMed

15.

Kalea AZ, Reiniger N, Yang H, Arriero M, Schmidt AM, Hudson BI: Alternative splicing of the murine receptor for advanced glycation end-products (RAGE) gene. FASEB J. 2009,

16.

Demling N, Ehrhardt C, Kasper M, Laue M, Knels L, Rieber E: Promotion of cell adherence and spreading: a novel function of RAGE, the highly selective differentiation marker of human alveolar epithelial type I cells. Cell and Tissue Research. 2006, 323: 475-488.PubMed

17.

Hudson BI, Carter AM, Harja E, Kalea AZ, Arriero M, Yang H, Grant PJ, Schmidt AM: Identification, classification, and expression of RAGE gene splice variants. FASEB J. 2008, 22: 1572-1580.PubMed

18.

Yan S, Ramasamy R, Schmidt A: Receptor for AGE (RAGE) and its ligands–cast into leading roles in diabetes and the inflammatory response. Journal of Molecular Medicine. 2009, 87: 235-247.PubMedCentralPubMed

19.

Bartling B, Hofmann H-S, Weigle B, Silber R-E, Simm A: Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma. Carcinogenesis. 2005, 26: 293-301.PubMed

20.

Englert JM, Hanford LE, Kaminski N, Tobolewski JM, Tan RJ, Fattman CL, Ramsgaard L, Richards TJ, Loutaev I, Nawroth PP, Kasper M, Bierhaus A, Oury TD: A Role for the Receptor for Advanced Glycation End Products in Idiopathic Pulmonary Fibrosis. Am J Pathol. 2008, 172: 583-591.PubMedCentralPubMed

21.

Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin J, Li H, Yasui K, Takeuchi M, Makita Z, Takasawa S, Okamoto H, Watanabe T, Yamamoto H: Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J. 2003, 370: 1097-1109.PubMedCentralPubMed

22.

Cheng C, Tsuneyama K, Kominami R, Shinohara H, Sakurai S, Yonekura H, Watanabe T, Takano Y, Yamamoto H, Yamamoto Y: Expression profiling of endogenous secretory receptor for advanced glycation end products in human organs. Mod Pathol. 2005, 18: 1385-1396.PubMed

23.

Harashima A, Yamamoto Y, Cheng C, Tsuneyama K, Myint KM, Takeuchi A, Yoshimura K, Li H, Watanabe T, Takasawa S, Okamoto H, Yonekura H, Yamamoto H: Identification of mouse orthologue of endogenous secretory receptor for advanced glycation end-products: structure, function and expression. Biochem J. 2006, 396: 109-115.PubMedCentralPubMed

24.

Neeper M, Schmidt A, Brett J, Yan S, Wang F, Pan Y, Elliston K, Stern D, Shaw A: Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem. 1992, 267: 14998-15004.PubMed

25.

Hanford LE, Enghild JJ, Valnickova Z, Petersen SV, Schaefer LM, Schaefer TM, Reinhart TA, Oury TD: Purification and Characterization of Mouse Soluble Receptor for Advanced Glycation End Products (sRAGE). J Biol Chem. 2004, 279: 50019-50024.PubMedCentralPubMed

26.

Englert JM, Ramsgaard L, Valnickova Z, Enghild JJ, Oury TD: Large scale isolation and purification of soluble RAGE from lung tissue. Protein Expr Purif. 2008, 61: 99-101.PubMedCentralPubMed

27.

Ostendorp T, Weibel M, Leclerc E, Kleinert P, Kroneck PMH, Heizmann CW, Fritz G: Expression and purification of the soluble isoform of human receptor for advanced glycation end products (sRAGE) from Pichia pastoris. Biochem Biophys Res Commun. 2006, 347 (1): 4-11.PubMed

28.

Kumano-Kuramochi M, Xie Q, Sakakibara Y, Niimi S, Sekizawa K, Komba S, Machida S: Expression and Characterization of Recombinant C-Terminal Biotinylated Extracellular Domain of Human Receptor for Advanced Glycation End Products (hsRAGE) in Escherichia coli. J Biochem. 2008, 143: 229-236.PubMed

29.

Pullerits R, Brisslert M, Jonsson I-M, Tarkowski A: Soluble receptor for advanced glycation end products triggers a proinflammatory cytokine cascade via beta2 integrin Mac-1. Arthritis Rheum. 2006, 54 (12): 3898-3907.PubMed

30.

Geroldi D, Falcone C, Emanuele E: Soluble Receptor for Advanced Glycation End Products: From Disease Marker to Potential Therapeutic Target. Current Medicinal Chemistry. 2006, 13: 1971-1978.PubMed

31.

Falcone C, Emanuele E, D'Angelo A, Buzzi MP, Belvito C, Cuccia M, Geroldi D: Plasma Levels of Soluble Receptor for Advanced Glycation End Products and Coronary Artery Disease in Nondiabetic Men. Arterioscler Thromb Vasc Biol. 2005, 25: 1032-1037.PubMed

32.

Hofmann M, Drury S, Fu C, Qu W, Taguchi A, Lu Y, Avila C, Kambham N, Bierhaus A, Nawroth P: RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell. 1999, 97: 889-901.PubMed

33.

Chavakis T, Bierhaus A, Nawroth PP: RAGE (receptor for advanced glycation end products): a central player in the inflammatory response. Microbes Infect. 2004, 6 (13): 1219-1225.PubMed

34.

Gebhardt C, Riehl A, Durchdewald M, Nemeth J, Furstenberger G, Muller-Decker K, Enk A, Arnold B, Bierhaus A, Nawroth PP, Hess J, Angel P: RAGE signaling sustains inflammation and promotes tumor development. J Exp Med. 2008, 205: 275-285.PubMedCentralPubMed

35.

Cecka JI: Serum-soluble receptor for advanced glycation end product levels in patients with amyotrophic lateral sclerosis. Acta Neurol Scand. 2008,

36.

Koyama H, Shoji T, Fukumoto S, Shinohara K, Shoji T, Emoto M, Mori K, Tahara H, Ishimura E, Kakiya R, Tabata T, Yamamoto H, Nishizawa Y: Low Circulating Endogenous Secretory Receptor for AGEs Predicts Cardiovascular Mortality in Patients With End-Stage Renal Disease. Arterioscler Thromb Vasc Biol. 2007, 27: 147-153.PubMed

37.

Nakamura K, Yamagishi S-i, Adachi H, Kurita-Nakamura Y, Matsui T, Yoshida T, Imaizumi T: Serum Levels of sRAGE, the Soluble Form of Receptor for Advanced Glycation End Products, Are Associated with Inflammatory Markers in Patients with Type 2 Diabetes. Molecular Medicine. 2007, 13: 185-189.PubMedCentralPubMed

38.

Nakamura K, Yamagishi S-i, Adachi H, Matsui T, Kurita-Nakamura Y, Takeuchi M, Inoue H, Imaizumi T: Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes. Microvascular Research. 2008, 76: 52-56.PubMed

39.

Humpert PM, Djuric Z, Kopf S, Rudofsky G, Morcos M, Nawroth PP, Bierhaus A: Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovascular Diabetology. 2007, 6: 9-PubMedCentralPubMed

40.

Brown LF, Fraser CG: Assay validation and biological variation of serum receptor for advanced glycation end-products. Ann Clin Biochem. 2008, 45: 518-519.PubMed

41.

Yamagishi S-i, Adachi H, Nakamura K, Matsui T, Jinnouchi Y, Takenaka K, Takeuchi M, Enomoto M, Furuki K, Hino A, Shigeto Y, Imaizumi T: Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism. 2006, 55: 1227-1231.PubMed

42.

Leclerc E, Fritz G, Weibel M, Heizmann CW, Galichet A: S100B and S100A6 Differentially Modulate Cell Survival by Interacting with Distinct RAGE (Receptor for Advanced Glycation End Products) Immunoglobulin Domains. J Biol Chem. 2007, 282: 31317-31331.PubMed

43.

Donato R: RAGE: A Single Receptor for Several Ligands and Different Cellular Responses: The Case of Certain S100 Proteins. Current Molecular Medicine. 2007, 7: 711-724.PubMed

44.

Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert P, Chen J, Hong M, Luther T, Henle T, Kloting I: Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes. 2001, 50: 2792-2808.PubMed

45.

Ramasamy R, Yan SF, Schmidt AM: Arguing for the motion: Yes, RAGE is a receptor for advanced glycation endproducts. Molecular Nutrition & Food Research. 2007, 51: 1111-1115.

46.

Logsdon C, Fuentes M, Huang E, Arumugam T: RAGE and RAGE ligands in cancer. Current Molecular Medicine. 2007, 7: 777-789.PubMed

47.

Santamaria-kisiel L, Rintala-dempsey AC, Shaw GS: Calcium-dependent and -independent interactions of the S100 protein family. Biochem J. 2006, 396: 201-214.PubMedCentralPubMed

48.

Ostendorp T, Leclerc E, Galichet A, Koch M, Demling N, Weigle B, Heizmann CW, Kroneck PMH, Fritz G: Structural and functional insights into RAGE activation by multimeric S100B. The EMBO Journal. 2007, 26: 3868-3878.PubMedCentralPubMed

49.

Xie J, Burz DS, He W, Bronstein IB, Lednev I, Shekhtman A: Hexameric Calgranulin C (S100A12) Binds to the Receptor for Advanced Glycated End Products (RAGE) Using Symmetric Hydrophobic Target-binding Patches. J Biol Chem. 2007, 282: 4218-4231.PubMed

50.

Salama I, Malone PS, Mihaimeed F, Jones JL: A review of the S100 proteins in cancer. European Journal of Surgical Oncology (EJSO). 2008, 34: 357-364.

51.

Sassano A, Platanias LC: Statins in tumor suppression. Cancer Letters. 2008, 260: 11-19.PubMed

52.

Goodwin Graham, Clive Sanders, Johns EW: A New Group of Chromatin-Associated Proteins with a High Content of Acidic and Basic Amino Acids. European Journal of Biochemistry. 1973, 38: 14-19.PubMed

53.

Hock R, Furusawa T, Ueda T, Bustin M: HMG chromosomal proteins in development and disease. Trends in Cell Biology. 2007, 17: 72-79.PubMedCentralPubMed

54.

Calogero S, Grassi F, Aguzzi A, Voigtländer T, Ferrier P, Ferrari S, Bianchi ME: The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nature Genetics. 1999, 22: 276-280.PubMed

55.

Muller S, Ronfani L, Bianchi ME: Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function. Journal of Internal Medicine. 2004, 255: 332-343.PubMed

56.

Cleynen I, Ven Van de WJM: The HMGA proteins: A myriad of functions. International Journal of Oncology. 2008, 32: 289-305.PubMed

57.

Fusco A, Fedele M: Roles of HMGA proteins in cancer. Nat Rev Cancer. 2007, 7: 899-910.PubMed

58.

Catena R, Escoffier E, Caron C, Khochbin S, Martianov I, Davidson I: HMGB4, A Novel Member of the HMGB Family, Is Preferentially Expressed in the Mouse Testis and Localizes to the Basal Pole of Elongating Spermatids. Biol Reprod. 2009, 80: 358-366.PubMed

59.

Hannappel E, Huff T: The thymosins. Prothymosin alpha, parathymosin, and beta-thymosins: structure and function. Vitam Horm. 2003, 66: 257-296.PubMed

60.

Piacentini M, Evangelisti C, Mastroberardino PG, Nardacci R, Kroemer G: Does prothymosin-[alpha] act as molecular switch between apoptosis and autophagy?. Cell Death Differ. 2003, 10: 937-939.PubMed

61.

Martic G, Karetsou Z, Kefala K, Politou AS, Clapier CR, Straub T, Papamarcaki T: Parathymosin Affects the Binding of Linker Histone H1 to Nucleosomes and Remodels Chromatin Structure. J Biol Chem. 2005, 280: 16143-16150.PubMed

62.

Lotze MT, Tracey KJ: High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005, 5: 331-342.PubMed

63.

Bustin M, Neihart NK: Antibodies against chromosomal HMG proteins stain the cytoplasm of mammalian cells. Cell. 1979, 16: 181-189.PubMed

64.

Pierantoni GM, Rinaldo C, Mottolese M, Di Benedetto A, Esposito F, Soddu S, Fusco A: High-mobility group A1 inhibits p53 by cytoplasmic relocalization of its proapoptotic activator HIPK2. Journal of Clinical Investigation. 2007, 117: 693-702.PubMedCentralPubMed

65.

Ellerman JE, Brown CK, de Vera M, Zeh HJ, Billiar T, Rubartelli A, Lotze MT: Masquerader: High Mobility Group Box-1 and Cancer. Clin Cancer Res. 2007, 13: 2836-2848.PubMed

66.

Sterner R, Vidali G, Allfrey VG: Discrete proteolytic cleavage of High Mobility Group proteins. Biochem Biophys Res Commun. 1979, 89: 129-133.PubMed

67.

Huan Y, Haichao W, Czura CJ, Tracey KJ: HMGB1 as a cytokine and therapeutic target. Journal of Endotoxin Research. 2002, 8: 469-472.

68.

Lotze MT, Zeh HJ, Rubartelli A, Sparvero LJ, Amoscato AA, Washburn NR, DeVera ME, Liang X, Tor M, Billiar T: The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunological Reviews. 2007, 220: 60-81.PubMed

69.

Yang H, Ochani M, Li J, Qiang X, Tanovic M, Harris HE, Susarla SM, Ulloa L, Wang H, DiRaimo R, Czura CJ, Wang H, Roth J, Warren HS, Fink MP, Fenton MJ, Andersson U, Tracey KJ: Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A. 2004, 101 (1): 296-301.PubMedCentralPubMed

70.

Wolffe AP: Acrhitectural regulations and Hmg1. Nature Genetics. 1999, 22: 215-217.PubMed

71.

Bonaldi T, Talamo F, Scaffidi P, Ferrera D, Porto A, Bachi A, Rubartelli A, Agresti A, Bianchi M: Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J. 2003, 22: 5551-5560.PubMedCentralPubMed

72.

Bianchi ME, Manfredi AA: High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunological Reviews. 2007, 220: 35-46.PubMed

73.

Topalova D, Ugrinova I, Pashev IG, Pasheva EA: HMGB1 protein inhibits DNA replication in vitro: A role of the acetylation and the acidic tail. The International Journal of Biochemistry & Cell Biology. 2008, 40: 1536-1542.

74.

Watson M, Stott K, Thomas JO: Mapping Intramolecular Interactions between Domains in HMGB1 using a Tail-truncation Approach. Journal of Molecular Biology. 2007, 374: 1286-1297.PubMed

75.

Pasheva E, Sarov M, Bidjekov K, Ugrinova I, Sarg B, Lindner H, Pashev IG: In Vitro Acetylation of HMGB-1 and -2 Proteins by CBP: the Role of the Acidic Tail. Biochemistry. 2004, 43: 2935-2940.PubMed

76.

Yu M, Wang H, Ding A, Golenbock D, Latz E, Czura C, Fenton M, Tracey K, Yang H: HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock. 2006, 26: 174-179.PubMed

77.

Ivanov S, Dragoi A-M, Wang X, Dallacosta C, Louten J, Musco G, Sitia G, Yap GS, Wan Y, Biron CA, Bianchi ME, Wang H, Chu W-M: A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood. 2007, 110: 1970-1981.PubMedCentralPubMed

78.

Abeyama K, Stern D, Ito Y, Kawahara K, Yoshimoto Y, Tanaka M, Uchimura T, Ida N, Yamazaki Y, Yamada S: The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest. 2005, 115: 1267-1274.PubMedCentralPubMed

79.

Sessa L, Bianchi ME: The evolution of High Mobility Group Box (HMGB) chromatin proteins in multicellular animals. Gene. 2007, 387: 133-140.PubMed

80.

Laudet V, Stehelin D, Clevers H: Ancestry and diversity of the HMG box superfamily. Nucl Acids Res. 1993, 21: 2493-2501.PubMedCentralPubMed

81.

Baxevanis AD, Landsman D: The HMG-1 box protein family: classification and functional relationships. Nucl Acids Res. 1995, 23: 1604-1613.PubMedCentralPubMed

82.

Wisniewski JR, Krohn NM, Heyduk E, Grasser KD, Heyduk T: HMG1 proteins from evolutionary distant organisms distort B-DNA conformation in similar way. Biochimica et Biophysica Acta (BBA) – Gene Structure and Expression. 1999, 1447: 25-34.

83.

Mosevitsky MI, Novitskaya VA, Iogannsen MG, Zabezhinsky MA: Tissue specificity of nucleo-cytoplasmic distribution of HMG1 and HMG2 proteins and their probable functions. European Journal of Biochemistry. 1989, 185: 303-310.PubMed

84.

Cheng BQ, Jia CQ, Liu CT, Lu XF, Zhong N, Zhang ZL, Fan W, Li YQ: Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Dig Liver Dis. 2008, 40 (6): 446-452.PubMed

85.

Hortin GL: The MALDI-TOF Mass Spectrometric View of the Plasma Proteome and Peptidome. Clin Chem. 2006, 52: 1223-1237.PubMed

86.

Zimmerman SB, Trach SO: Estimation of macromolecule concentrations and excluded volume effects for the cytoplasm of Escherichia coli. Journal of Molecular Biology. 1991, 222: 599-620.PubMed

87.

Scaffidi P, Misteli T, Bianchi ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002, 418: 191-195.PubMed

88.

Bell CW, Jiang W, Reich CF, Pisetsky DS: The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol. 2006, 291: C1318-1325.PubMed

89.

Zeh HJ, Lotze MT: Addicted to death: invasive cancer and the immune response to unscheduled cell death. Journal of Immunotherapy. 2005, 28: 1-9.PubMed

90.

Wang H, Bloom O, Zhang M, Vishnubhakat J, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L: HMGB-1 as a late mediator of endotoxin lethality in mice. Science. 1999, 285: 248-251.PubMed

91.

van Beijnum J, Buurman W, Griffioen A: Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis. 2008, 11: 91-99.PubMed

92.

Tang D, Shi Y, Kang R, Li T, Xiao W, Wang H, Xiao X: Hydrogen peroxide stimulates macrophages and monocytes to actively release HMGB1. J Leukoc Biol. 2007, 81: 741-747.PubMedCentralPubMed

93.

DeMarco RA, Fink MP, Lotze MT: Monocytes promote natural killer cell interferon gamma production in response to the endogenous danger signal HMGB1. Molecular Immunology. 2005, 42: 433-444.PubMed

94.

Ito T, Kawahara K-i, Okamoto K, Yamada S, Yasuda M, Imaizumi H, Nawa Y, Meng X, Shrestha B, Hashiguchi T, Maruyama I: Proteolytic Cleavage of High Mobility Group Box 1 Protein by Thrombin-Thrombomodulin Complexes. Arteriosclerosis, Thrombosis, and Vascular Biology. 2008, 28: 1825-1830.PubMed

95.

Huttunen HJ, Fages C, Kuja-Panula J, Ridley AJ, Rauvala H: Receptor for Advanced Glycation End Products-binding COOH-terminal Motif of Amphoterin Inhibits Invasive Migration and Metastasis. Cancer Res. 2002, 62: 4805-4811.PubMed

96.

Yuan Z, Chen J, Zhang Y, Peng Y: Construction and characterization of the HMGB1 mutant as a competitive antagonist to HMGB1 induced cytokines release. Biochem Biophys Res Commun. 2008, 372 (4): 703-707.PubMed

97.

Leclerc E, Fritz G, Vetter SW, Heizmann CW: Binding of S100 proteins to RAGE: An update. Biochim Biophys Acta. 2009,

98.

Donato R: S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. The International Journal of Biochemistry & Cell Biology. 2001, 33: 637-668.

99.

Moore BW: A soluble protein characteristic of the nervous system. Biochem Biophys Res Commun. 1965, 19 (6): 739-744.PubMed

100.

Schafer BW, Wicki R, Engelkamp D, Mattei M-G, Heizmann CW: Isolation of a YAC clone covering a cluster of nine S100 genes on human chromosome 1q21: rationale for a new nomenclature of the S100 calcium-binding protein family. Genomics. 1995, 25: 638-643.PubMed

101.

Heizmann CW, Ackermann GE, Galichet A: Pathologies Involving the S100 Proteins and RAGE. Calcium Signalling and Disease: Molecular Pathology of Calcium. 2007, Springer Netherlands, 45: 93-138.

102.

Eckert RL, Broome A-M, Ruse M, Robinson N, Ryan D, Lee K: S100 Proteins in the Epidermis. Journal of Investigative Dermatology. 2003, 123: 23-33.

103.

Foell D, Wittkowski H, Vogl T, Roth J: S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol. 2007, 81: 28-37.PubMed

104.

Fernandez-Fernandez MR, Rutherford TJ, Fersht AR: Members of the S100 family bind p53 in two distinct ways. Protein Science. 2008, 17: 1663-1670.PubMedCentralPubMed

105.

Yan SS, Wu Z-Y, Zhang HP, Furtado G, Chen X, Yan SF, Schmidt AM, Brown C, Stern A, Lafaille J, Chess L, Stern DM, Jiang H: Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system. Nature Medicine. 2003, 9: 287-293.PubMed

106.

Franz C, Durussel I, Cox JA, Schafer BW, Heizmann CW: Binding of Ca2+ and Zn2+ to Human Nuclear S100A2 and Mutant Proteins. J Biol Chem. 1998, 273: 18826-18834.PubMed

107.

Koch M, Bhattacharya S, Kehl T, Gimona M, Vasak M, Chazin W, Heizmann CW, Kroneck PMH, Fritz G: Implications on zinc binding to S100A2. Biochim Biophys Acta. 2007, 1773: 457-470.PubMed

108.

Schafer BW, Fritschy J-M, Murmann P, Troxler H, Durussel I, Heizmann CW, Cox JA: Brain S100A5 Is a Novel Calcium-, Zinc-, and Copper Ion-binding Protein of the EF-hand Superfamily. J Biol Chem. 2000, 275: 30623-30630.PubMed

109.

Rescher U, Gerke V: S100A10/p11: family, friends and functions. Pflügers Archiv European Journal of Physiology. 2008, 455: 575-582.PubMed

110.

Yamada A, Irie K, Hirota T, Ooshio T, Fukuhara A, Takai Y: Involvement of the Annexin II-S100A10 Complex in the Formation of E-cadherin-based Adherens Junctions in Madin-Darby Canine Kidney Cells. J Biol Chem. 2005, 280: 6016-6027.PubMed

111.

Pietas A, Schlüns K, Marenholz I, Schäfer BW, Heizmann CW, Petersen I: Molecular Cloning and Characterization of the Human S100A14 Gene Encoding a Novel Member of the S100 Family. Genomics. 2002, 79: 513-522.PubMed

112.

Sturchler E, Cox JA, Durussel I, Weibel M, Heizmann CW: S100A16, a Novel Calcium-binding Protein of the EF-hand Superfamily. J Biol Chem. 2006, 281: 38905-38917.PubMed

113.

Marenholz I, Lovering RC, Heizmann CW: An update of the S100 nomenclature. Biochim Biophys Acta. 2006, 1763 (11): 1282-1283.PubMed

114.

Choi K-C, Leung PC, Jeung E-B: Biology and physiology of Calbindin-D9k in female reproductive tissues: Involvement of steroids and endocrine disruptors. Reprod Biol Endocrinol. 2005, 3: 66-PubMedCentralPubMed

115.

Gribenko AV, Hopper JE, Makhatadze GI: Molecular Characterization and Tissue Distribution of a Novel Member of the S100 Family of EF-Hand Proteins. Biochemistry. 2001, 40: 15538-15548.PubMed

116.

Wang G, Zhang S, Fernig DG, Martin-Fernandez M, Rudland PS, Barraclough R: Mutually antagonistic actions of S100A4 and S100A1 on normal and metastatic phenotypes. Oncogene. 2004, 24: 1445-1454.

117.

Hoppmann S, Haase C, Richter S, Pietzsch J: Expression, purification and fluorine-18 radiolabeling of recombinant S100 proteins–potential probes for molecular imaging of receptor for advanced glycation endproducts (RAGE) in vivo. Protein Expr Purif. 2008, 57: 143-152.PubMed

118.

Ghavami S, Rashedi I, Dattilo BM, Eshraghi M, Chazin WJ, Hashemi M, Wesselborg S, Kerkhoff C, Los M: S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway. J Leukoc Biol. 2008, 83: 1484-1492.PubMedCentralPubMed

119.

Andrassy M, Igwe J, Autschbach F, Volz C, Remppis A, Neurath MF, Schleicher E, Humpert PM, Wendt T, Liliensiek B, Morcos M, Schiekofer S, Thiele K, Chen J, Kientsch-Engel R, Schmidt A-M, Stremmel W, Stern DM, Katus HA, Nawroth PP, Bierhaus A: Posttranslationally Modified Proteins as Mediators of Sustained Intestinal Inflammation. Am J Pathol. 2006, 169: 1223-1237.PubMedCentralPubMed

120.

Turovskaya O, Foell D, Sinha P, Vogl T, Newlin R, Nayak J, Nguyen M, Olsson A, Nawroth PP, Bierhaus A, Varki N, Kronenberg M, Freeze HH, Srikrishna G: RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis. 2008, 29: 2035-2043.PubMedCentralPubMed

121.

Donato R: Intracellular and extracellular roles of S100 proteins. Microsc Res Tech. 2003, 60 (6): 540-551.PubMed

122.

Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen MAD, Nacken W, Foell D, Poll van der T, Sorg C, Roth J: Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med. 2007, 13: 1042-1049.PubMed

123.

Hiratsuka S, Watanabe A, Aburatani H, Maru Y: Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nature Cell Biology. 2006, 8: 1369-1375.PubMed

124.

Yammani RR, Carlson CS, Bresnick AR, Loeser RF: Increase in production of matrix metalloproteinase 13 by human articular chondrocytes due to stimulation with S100A4: Role of the receptor for advanced glycation end products. Arthritis Rheum. 2006, 54 (9): 2901-2911.PubMed

125.

Omori K, Ohira T, Uchida Y, Ayilavarapu S, Batista EL, Yagi M, Iwata T, Liu H, Hasturk H, Kantarci A, Van Dyke TE: Priming of neutrophil oxidative burst in diabetes requires preassembly of the NADPH oxidase. Journal of Leukocyte Biology. 2008, 84: 292-301.PubMedCentralPubMed

126.

Wolf R, Howard OMZ, Dong H-F, Voscopoulos C, Boeshans K, Winston J, Divi R, Gunsior M, Goldsmith P, Ahvazi B, Chavakis T, Oppenheim JJ, Yuspa SH: Chemotactic Activity of S100A7 (Psoriasin) Is Mediated by the Receptor for Advanced Glycation End Products and Potentiates Inflammation with Highly Homologous but Functionally Distinct S100A15. J Immunol. 2008, 181: 1499-1506.PubMedCentralPubMed

127.

Carlsson H, Petersson S, Enerbäck C: Cluster analysis of S100 gene expression and genes correlating to psoriasin (S100A7) expression at different stages of breast cancer development. International Journal of Oncology. 2005, 27: 1473-1481.PubMed

128.

Lee KC, Eckert RL: S100A7 (Psoriasin) – Mechanism of Antibacterial Action in Wounds. J Invest Dermatol. 2006, 127: 945-957.PubMed

129.

Sakaguchi M, Sonegawa H, Murata H, Kitazoe M, Futami J-i, Kataoka K, Yamada H, Huh N-h: S100A11, an Dual Mediator for Growth Regulation of Human Keratinocytes. Mol Biol Cell. 2008, 19: 78-85.PubMedCentralPubMed

130.

Pan J, Rintala-Dempsey AC, Li Y, Shaw GS, Konermann L: Folding Kinetics of the S100A11 Protein Dimer Studied by Time-Resolved Electrospray Mass Spectrometry and Pulsed Hydrogen-Deuterium Exchange. Biochemistry. 2006, 45: 3005-3013.PubMed

131.

Cecil DL, Terkeltaub R: Transamidation by Transglutaminase 2 Transforms S100A11 Calgranulin into a Procatabolic Cytokine for Chondrocytes. J Immunol. 2008, 180: 8378-8385.PubMedCentralPubMed

132.

Fuellen G, Foell D, Nacken W, Sorg C, Kerkhoff C: Absence of S100A12 in mouse: implications for RAGE-S100A12 interaction. Trends in Immunology. 2003, 24: 622-624.PubMed

133.

Moroz OV, Dodson GG, Wilson KS, Lukanidin E, Bronstein IB: Multiple structural states of S100A12: A key to its functional diversity. Microsc Res Tech. 2003, 60: 581-592.PubMed

134.

Yan WX, Armishaw C, Goyette J, Yang Z, Cai H, Alewood P, Geczy CL: Mast Cell and Monocyte Recruitment by S100A12 and Its Hinge Domain. J Biol Chem. 2008, 283: 13035-13043.PubMed

135.

Moroz OV, Antson AA, Dodson EJ, Burrell HJ, Grist SJ, Lloyd RM, Maitland NJ, Dodson GG, Wilson KS, Lukanidin E, Bronstein IB: The structure of S100A12 in a hexameric form and its proposed role in receptor signalling. Acta Crystallogr D Biol Crystallogr. 2002, 58: 407-413.PubMed

136.

Shishibori T, Oyama Y, Matsushita O, Yamashita K, Furuichi H, Okabe A, Maeta H, Hata Y, Kobayashi R: Three distinct anti-allergic drugs, amlexanox, cromolyn and tranilast, bind to S100A12 and S100A13 of the S100 protein family. Biochem J. 1999, 338: 583-589.PubMedCentralPubMed

137.

Hayrabedyan S, Kyurkchiev S, Kehayov I: FGF-1 and S100A13 possibly contribute to angiogenesis in endometriosis. Journal of Reproductive Immunology. 2005, 67: 87-101.PubMed

138.

Arnesano F, Banci L, Bertini I, Fantoni A, Tenori L, Viezzoli MS: Structural Interplay between Calcium(II) and Copper(II) Binding to S100A13 Protein. Angew Chem Int Ed Engl. 2005, 44: 6341-6344.PubMed

139.

Landriscina M, Schinzari G, Di Leonardo G, Quirino M, Cassano A, D'Argento E, Lauriola L, Scerrati M, Prudovsky I, Barone C: S100A13, a new marker of angiogenesis in human astrocytic gliomas. Journal of Neuro-Oncology. 2006, 80: 251-259.PubMed

140.

Maczurek A, Shanmugam K, Munch G: Inflammation and the Redox-sensitive AGE-RAGE Pathway as a Therapeutic Target in Alzheimer's Disease. Annals of the New York Academy of Sciences. 2008, 1126: 147-151.PubMed

141.

Leite MC, Galland F, Brolese G, Guerra MC, Bortolotto JW, Freitas R, Almeida LMVd, Gottfried C, Goncalves C-A: A simple, sensitive and widely applicable ELISA for S100B: Methodological features of the measurement of this glial protein. Journal of Neuroscience Methods. 2008, 169: 93-99.PubMed

142.

Goncalves C-A, Concli Leite M, Nardin P: Biological and methodological features of the measurement of S100B, a putative marker of brain injury. Clinical Biochemistry. 2008, 41: 755-763.PubMed

143.

Bianchi R, Giambanco I, Donato R: S100B/RAGE-dependent activation of microglia via NF-[kappa]B and AP-1: Co-regulation of COX-2 expression by S100B, IL-1[beta] and TNF-[alpha]. Neurobiology of Aging. 2009,

144.

Huttunen H, Kuja-Panula J, Sorci G, Agneletti A, Donato R, Rauvala H: Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J Biol Chem. 2000, 275: 40096-40105.PubMed

145.

Businaro R, Leone S, Fabrizi C, Sorci G, Donato R, Lauro GM, Fumagalli L: S100B protects LAN-5 neuroblastoma cells against Abeta amyloid-induced neurotoxicity via RAGE engagement at low doses but increases Abeta amyloid neurotoxicity at high doses. Journal of Neuroscience Research. 2006, 83: 897-906.PubMed

146.

Arumugam T, Simeone D, Schmidt A, Logsdon C: S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE). J Biol Chem. 2004, 279: 5059-5065.PubMed

147.

Parkkila S, Pan P-W, Ward A, Gibadulinova A, Oveckova I, Pastorekova S, Pastorek J, Martinez A, Helin H, Isola J: The calcium-binding protein S100P in normal and malignant human tissues. BMC Clinical Pathology. 2008, 8: 2-PubMedCentralPubMed

148.

Bartling B, Rehbein G, Schmitt WD, Hofmann H-S, Silber R-E, Simm A: S100A2-S100P expression profile and diagnosis of non-small cell lung carcinoma: Impairment by advanced tumour stages and neoadjuvant chemotherapy. European Journal of Cancer. 2007, 43: 1935-1943.PubMed

149.

Fuentes M, Nigavekar S, Arumugam T, Logsdon C, Schmidt A, Park J, Huang E: RAGE Activation by S100P in Colon Cancer Stimulates Growth, Migration, and Cell Signaling Pathways. Dis Colon Rectum. 2007, 50: 1230-1240.PubMed

150.

Arumugam T, Ramachandran V, Logsdon CD: Effect of Cromolyn on S100P Interactions With RAGE and Pancreatic Cancer Growth and Invasion in Mouse Models. J Natl Cancer Inst. 2006, 98: 1806-1818.PubMedCentralPubMed

151.

Namba T, Homan T, Nishimura T, Mima S, Hoshino T, Mizushima T: Up-regulation of S100P expression by non-steroidal anti-inflammatory drugs and its role in their anti-tumorigenic effects. J Biol Chem. 2008, 284 (7): 4158-4167.PubMed

152.

Verdier Y, Zarandi M, Penke B: Amyloid beta-peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer's disease. Journal of Peptide Science. 2004, 10: 229-248.PubMed

153.

Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL, Stern D: Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb. 1994, 14: 1521-1528.PubMed

154.

Du Yan S, Zhu H, Fu J, Yan SF, Roher A, Tourtellotte WW, Rajavashisth T, Chen X, Godman GC, Stern D, Schmidt AM: Amyloid-beta peptide receptor for Advanced Glycation Endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: A proinflammatory pathway in Alzheimer's Disease. Proceedings of the National Academy of Sciences of the United States of America. 1997, 94: 5296-5301.PubMedCentralPubMed

155.

Liu Y, Dargusch R, Schubert D: Beta Amyloid Toxicity Does Not Require RAGE Protein. Biochemical and Biophysical Research Communications. 1997, 237: 37-40.PubMed

156.

Sturchler E, Galichet A, Weibel M, Leclerc E, Heizmann CW: Site-Specific Blockade of RAGE-Vd Prevents Amyloid-{beta} Oligomer Neurotoxicity. J Neurosci. 2008, 28: 5149-5158.PubMed

157.

Queisser MA, Kouri FM, Konigshoff M, Wygrecka M, Schubert U, Eickelberg O, Preissner KT: Loss of RAGE in Pulmonary Fibrosis: Molecular Relations to Functional Changes in Pulmonary Cell Types. Am J Respir Cell Mol Biol. 2008, 39: 337-345.PubMed

158.

He M, Kubo H, Ishizawa K, Hegab AE, Yamamoto Y, Yamamoto H, Yamaya M: The role of the receptor for advanced glycation end-products in lung fibrosis. Am J Physiol Lung Cell Mol Physiol. 2007, 293: L1427-L1436.PubMed

159.

Singh R, Barden A, Mori T, Beilin L: Advanced glycation end-products: a review. Diabetologia. 2001, 44: 129-146.PubMed

160.

Zhang Q, Ames JM, Smith RD, Baynes JW, Metz TO: A Perspective on the Maillard Reaction and the Analysis of Protein Glycation by Mass Spectrometry: Probing the Pathogenesis of Chronic Disease. Journal of Proteome Research. 2009, 8: 754-769.PubMedCentralPubMed

161.

Goldin A, Beckman JA, Schmidt AM, Creager MA: Advanced Glycation End Products: Sparking the Development of Diabetic Vascular Injury. Circulation. 2006, 114: 597-605.PubMed

162.

Noiri E, Tsukahara H: Parameters for measurement of oxidative stress in diabetes mellitus: applicability of enzyme-linked immunosorbent assay for clinical evaluation. Journal of Investigative Medicine. 2005, 53: 167-175.PubMed

163.

Asahi K, Ichimori K, Nakazawa H, Izuhara Y, Inagi R, Watanabe T, Miyata T, Kurokawa K: Nitric oxide inhibits the formation of advanced glycation end products. Kidney International. 2000, 58: 1780-1787.PubMed

164.

Peyroux J, Sternberg M: Advanced glycation endproducts (AGEs): pharmacological inhibition in diabetes. Pathologie Biologie. 2006, 54: 405-419.PubMed

165.

Ulrich P, Cerami A: Protein Glycation, Diabetes, and Aging. Recent Prog Horm Res. 2001, 56: 1-22.PubMed

166.

Hori O, Brett J, Slattery T, Cao R, Zhang J, Chen J, Nagashima M, Lundh E, Vijay S, Nitecki D: The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem. 1995, 270: 25752-25761.PubMed

167.

Collison KS, Parhar RS, Saleh SS, Meyer BF, Kwaasi AA, Hammami MM, Schmidt AM, Stern DM, Al-Mohanna FA: RAGE-mediated neutrophil dysfunction is evoked by advanced glycation end products (AGEs). J Leukoc Biol. 2002, 71: 433-444.PubMed

168.

Ramasamy R, Vannucci SJ, Yan SSD, Herold K, Yan SF, Schmidt AM: Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology. 2005, 15: 16R-28R.PubMed

169.

Bartrons R, Caro J: Hypoxia, glucose metabolism and the Warburg's effect. J Bioenerg Biomembr. 2007, 39: 223-229.PubMed

170.

Hsu PP, Sabatini DM: Cancer Cell Metabolism: Warburg and Beyond. Cell. 2008, 134: 703-707.PubMed

171.

Uetz-von Allmen E, Koch M, Fritz G, Legler DF: V domain of RAGE interacts with AGEs on prostate carcinoma cells. The Prostate. 2008, 68: 748-758.

172.

Heijst JWJ, Niessen HWM, Hoekman K, Schalkwijk CG: Advanced Glycation End Products in Human Cancer Tissues: Detection of N-epsilon-(Carboxymethyl)lysine and Argpyrimidine. Annals of the New York Academy of Sciences. 2005, 1043: 725-733.PubMed

173.

Touré F, Zahm J, Garnotel R, Lambert E, Bonnet N, Schmidt A, Vitry F, Chanard J, Gillery P, P R: Receptor for Advanced Glycation end products (RAGE) modulates neutrophil adhesion and migration on Glycoxidated extracellular matrix. Biochem J. 2008, 416: 255-261.PubMed

174.

de la Fuente JA, Manzanaro S, Martin MJ, de Quesada TG, Reymundo I, Luengo SM, Gago F: Synthesis, Activity, and Molecular Modeling Studies of Novel Human Aldose Reductase Inhibitors Based on a Marine Natural Product. Journal of Medicinal Chemistry. 2003, 46: 5208-5221.PubMed

175.

Webster RD: New Insights into the Oxidative Electrochemistry of Vitamin E. Accounts of Chemical Research. 2007, 40: 251-257.PubMed

176.

Chen Y, Yan SS, Colgan J, Zhang H-P, Luban J, Schmidt AM, Stern D, Herold KC: Blockade of Late Stages of Autoimmune Diabetes by Inhibition of the Receptor for Advanced Glycation End Products. J Immunol. 2004, 173: 1399-1405.PubMed

177.

Freedman BI, Hicks PJ, Sale MM, Pierson ED, Langefeld CD, Rich SS, Xu J, McDonough C, Janssen B, Yard BA, Woude van der FJ, Bowden DW: A leucine repeat in the carnosinase gene CNDP1 is associated with diabetic end-stage renal disease in European Americans. Nephrol Dial Transplant. 2007, 22: 1131-1135.PubMed

178.

Bierhaus A, Haslbeck K-M, Humpert PM, Liliensiek B, Dehmer T, Morcos M, Sayed AAR, Andrassy M, Schiekofer S, Schneider JG, Schulz JB, Heuss D, Neundörfer B, Dierl S, Huber J, Tritschler H, Schmidt A-M, Schwaninger M, Haering H-U, Schleicher E, Kasper M, Stern DM, Arnold B, Nawroth PP: Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. Journal of Clinical Investigation. 2004, 114: 1741-1751.PubMedCentralPubMed

179.

Chou DKH, Zhang J, Smith FI, McCaffery P, Jungalwala FB: Developmental expression of receptor for advanced glycation end products (RAGE), amphoterin and sulfoglucuronyl (HNK-1) carbohydrate in mouse cerebellum and their role in neurite outgrowth and cell migration. Journal of Neurochemistry. 2004, 90: 1389-1401.PubMed

180.

Zhai D-X, Kong Q-F, Xu W-S, Bai S-S, Peng H-S, Zhao K, Li G-Z, Wang D-D, Sun B, Wang J-H, Wang G-Y, Li H-L: RAGE expression is up-regulated in human cerebral ischemia and pMCAO rats. Neuroscience Letters. 2008, 445: 117-121.PubMed

181.

Haslbeck KM, Bierhaus A, Erwin S, Kirchner A, Nawroth P, Schluzer U, Neundufer B, Heuss D: Receptor for advanced glycation endproduct (RAGE)-mediated nuclear factor-kappaB activation in vasculitic neuropathy. Muscle & Nerve. 2004, 29: 853-860.

182.

Haslbeck KM, Neundörfer B, Schlötzer-Schrehardt U, Bierhaus A, Schleicher E, Pauli E, Haslbeck M, Hecht M, Nawroth P, Heuss D: Activation of the RAGE pathway: a general mechanism in the pathogenesis of polyneuropathies?. Neurological Research. 2007, 29: 103-110.PubMed

183.

Taguchi A, Blood D, del Toro G, Canet A, Lee D, Qu W, Tanji N, Lu Y, Lalla E, Fu C: Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature. 2000, 405: 354-360.PubMed

184.

Tateno T, Ueno S, Hiwatashi K, Matsumoto M, Okumura H, Setoyama T, Uchikado Y, Sakoda M, Kubo F, Ishigami S, Shinchi H, Natsugoe S: Expression of Receptor for Advanced Glycation End Products (RAGE) is Related to Prognosis in Patients with Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology. 2009, 16: 440-446.PubMed

185.

Bartling B, Demling N, Silber R-E, Simm A: Proliferative Stimulus of Lung Fibroblasts on Lung Cancer Cells Is Impaired by the Receptor for Advanced Glycation End-Products. Am J Respir Cell Mol Biol. 2006, 34: 83-91.PubMed

186.

Abe R, Shimizu T, Sugawara H, Watanabe H, Nakamura H, Choei H, Sasaki N, Yamagishi S-i, Takeuchi M, Shimizu H: Regulation of Human Melanoma Growth and Metastasis by AGE-AGE Receptor Interactions. J Investig Dermatol. 2004, 122: 461-467.PubMed

187.

Riuzzi F, Sorci G, Donato R: The Amphoterin (HMGB1)/Receptor for Advanced Glycation End Products (RAGE) Pair Modulates Myoblast Proliferation, Apoptosis, Adhesiveness, Migration, and Invasiveness: Functional Inactivation of RAGE in L6 Myoblasts Results in Tumor Formation in vivo. J Biol Chem. 2006, 281: 8242-8253.PubMed

188.

Ramasamy R, Yan SF, Herold K, Clynes R, Schmidt AM: Receptor for Advanced Glycation End Products: Fundamental Roles in the Inflammatory Response: Winding the Way to the Pathogenesis of Endothelial Dysfunction and Atherosclerosis. Ann NY Acad Sci. 2008, 1126: 7-13.PubMedCentralPubMed

189.

Chen Y, Akirav EM, Chen W, Henegariu O, Moser B, Desai D, Shen JM, Webster JC, Andrews RC, Mjalli AM, Rothlein R, Schmidt AM, Clynes R, Herold KC: RAGE Ligation Affects T Cell Activation and Controls T Cell Differentiation. J Immunol. 2008, 181: 4272-4278.PubMedCentralPubMed

190.

Chavakis T, Bierhaus A, Al-Fakhri N, Schneider D, Witte S, Linn T, Nagashima M, Morser J, Arnold B, Preissner K: The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med. 2003, 198: 1507-1515.PubMedCentralPubMed

191.

Manfredi AA, Capobianco A, Esposito A, De Cobelli F, Canu T, Monno A, Raucci A, Sanvito F, Doglioni C, Nawroth PP, Bierhaus A, Bianchi ME, Rovere-Querini P, Del Maschio A: Maturing Dendritic Cells Depend on RAGE for In Vivo Homing to Lymph Nodes. J Immunol. 2008, 180: 2270-2275.PubMed

Title: RAGE (Receptor for Advanced Glycation Endproducts), RAGE Ligands, and their role in Cancer and Inflammation
Authors: Louis J Sparvero
Denise Asafu-Adjei
Rui Kang
Daolin Tang
Neilay Amin
Jaehyun Im
Ronnye Rutledge
Brenda Lin
Andrew A Amoscato
Herbert J Zeh
Michael T Lotze
Publication date: 01-12-2009
Publisher: BioMed Central
Published in: Journal of Translational Medicine / Issue 1/2009
Electronic ISSN: 1479-5876
DOI: https://doi.org/10.1186/1479-5876-7-17

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2009

Gene and microRNA analysis of neutrophils from patients with polycythemia vera and essential thrombocytosis: down-regulation of micro RNA-1 and -133a

Angiostatin anti-angiogenesis requires IL-12: The innate immune system as a key target

yuDetecting the percent of peripheral blood mononuclear cells displaying p-STAT-3 in malignant glioma patients

Drugs targeting the mitochondrial pore act as citotoxic and cytostatic agents in temozolomide-resistant glioma cells

Molecular analysis of the apoptotic effects of BPA in acute myeloid leukemia cells

Species distribution and antimicrobial susceptibility of gram-negative aerobic bacteria in hospitalized cancer patients

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials